Linked Life Data

11286465

Source:http://linkedlifedata.com/resource/pubmed/id/11286465

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
7
pubmed:dateCreated
2001-4-5
pubmed:abstractText
Variant liver oestrogen receptor transcripts in hepatocellular carcinoma are associated with aggressive clinical course and unresponsiveness to tamoxifen. To evaluate the impact on survival and on tumour growth of megestrol (progestin drug acting at post-receptorial level) we enrolled 45 patients with HCC characterized by variant liver oestrogen receptors in a prospective, randomized study with megestrol vs. placebo. Presence of variant oestrogen receptors was determined by RT/PCR. 24 patients were randomized to no treatment and 21 to therapy with megestrol 160 mg day(-1). Results were analysed by Kaplan-Meier and Cox methods. Survival of hepatocellular carcinoma characterized by variant oestrogen receptors was extremely poor (median survival 7 months); megestrol significantly improved survival (18 months) (P = 0.0090). Tumour growth at one year was significantly slowed down in megestrol-treated patients (P = 0.0212). Bilirubin levels, presence of portal thrombosis, HBV aetiology and treatment were identified at univariate analysis as factors significantly associated with survival; at multivariate analysis, only megestrol therapy (P = 0.0003), presence of HBV infection (P = 0.0009) and presence of portal vein thrombosis (P = 0.0051) were factors independently related with survival. (1) Megestrol slows down the aggressive tumour growth of patients with hepatocellular carcinoma characterized by variant estrogen receptors and (2) is also able to favourably influence the course of disease, more than doubling median survival.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/11286465-11720452, http://linkedlifedata.com/resource/pubmed/commentcorrection/11286465-1322349, http://linkedlifedata.com/resource/pubmed/commentcorrection/11286465-1705274, http://linkedlifedata.com/resource/pubmed/commentcorrection/11286465-1988075, http://linkedlifedata.com/resource/pubmed/commentcorrection/11286465-2160313, http://linkedlifedata.com/resource/pubmed/commentcorrection/11286465-2839286, http://linkedlifedata.com/resource/pubmed/commentcorrection/11286465-2861313, http://linkedlifedata.com/resource/pubmed/commentcorrection/11286465-7657122, http://linkedlifedata.com/resource/pubmed/commentcorrection/11286465-7834616, http://linkedlifedata.com/resource/pubmed/commentcorrection/11286465-7930468, http://linkedlifedata.com/resource/pubmed/commentcorrection/11286465-8032079, http://linkedlifedata.com/resource/pubmed/commentcorrection/11286465-8225217, http://linkedlifedata.com/resource/pubmed/commentcorrection/11286465-8594428, http://linkedlifedata.com/resource/pubmed/commentcorrection/11286465-8698219, http://linkedlifedata.com/resource/pubmed/commentcorrection/11286465-8752151, http://linkedlifedata.com/resource/pubmed/commentcorrection/11286465-9093719, http://linkedlifedata.com/resource/pubmed/commentcorrection/11286465-9195366, http://linkedlifedata.com/resource/pubmed/commentcorrection/11286465-9537437
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
0007-0920
pubmed:author
pubmed:copyrightInfo
Copyright 2001 Cancer Research Campaign.
pubmed:issnType
Print
pubmed:day
6
pubmed:volume
84
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
881-5
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
2001
pubmed:articleTitle
Hormonal therapy with megestrol in inoperable hepatocellular carcinoma characterized by variant oestrogen receptors.
pubmed:affiliation
Department of Internal Medicine, University of Modena, Italy.
pubmed:publicationType
Journal Article, Clinical Trial, Randomized Controlled Trial, Research Support, Non-U.S. Gov't